New insights on sorafenib resistance in liver cancer with correlation of individualized therapy

被引：97

作者：

Zhang Cheng ^{[1
,2
]}

Jiang Wei-Qi ^{[1
]}

Ding Jin ^{[1
,2
]}

机构：

[1] Second Mil Med Univ, Eastern Hepatobiliary Surg Hosp Inst, Int Cooperat Lab Signal Transduct, Shanghai 200433, Peoples R China

[2] Natl Ctr Liver Canc, Shanghai 200433, Peoples R China

来源：

BIOCHIMICA ET BIOPHYSICA ACTA-REVIEWS ON CANCER | 2020年 / 1874卷 / 01期

关键词：

Liver cancer; Sorafenib; Chemoresistance; Individualized therapy; ADVANCED HEPATOCELLULAR-CARCINOMA; MULTIDRUG-RESISTANCE; DRUG-RESISTANCE; STEM-CELL; PHOSPHORYLATED ERK; AUTOPHAGY; EFFICACY; RECEPTOR; SENSITIVITY; INHIBITION;

D O I：

10.1016/j.bbcan.2020.188382

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Liver cancer is highly malignant and insensitive to cytotoxic chemotherapy and is associated with very poor patient prognosis. In 2007, the small-molecule targeted drug sorafenib was approved for the treatment of advanced liver cancer. In the subsequent ten years, sorafenib has been the only first-line therapeutic targeted drug for advanced hepatocellular carcinoma (HCC). However, a number of clinical studies show that a considerable percentage of patients with liver cancer are insensitive to sorafenib. The number of patients who actually benefit significantly from sorafenib treatment is very limited, and the overall efficacy of sorafenib is far from satisfactory, which has attracted the attention of researchers. Based on previous studies and reports, this article reviews the potential mechanisms of sorafenib resistance (SR) and summarizes the biomarkers and clinicopathological indicators that might be used for predicting sorafenib response and developing personalized therapy.

引用

页数：8

共 138 条

[81] Melatonin-induced increase in sensitivity of human hepatocellular carcinoma cells to sorafenib is associated with reactive oxygen species production and mitophagy [J].

Prieto-Dominguez, Nestor ;

Ordonez, Raquel ;

Fernandez, Anna ;

Mendez-Blanco, Carolina ;

Baulies, Anna ;

Garcia-Ruiz, Carmen ;

Fernandez-Checa, Jose C. ;

Mauriz, Jose L. ;

Gonzalez-Gallego, Javier .

JOURNAL OF PINEAL RESEARCH, 2016, 61 (03) :396-407

[82] Reversal of sorafenib resistance in hepatocellular carcinoma: epigenetically regulated disruption of 14-3-3η/hypoxia-inducible factor-1α [J].

Qiu, Yongxin ;

Shan, Wenqi ;

Yang, Ye ;

Jin, Ming ;

Dai, Yi ;

Yang, Hanyu ;

Jiao, Ruonan ;

Xia, Yunwei ;

Liu, Qinqiang ;

Ju, Liang ;

Huang, Guangming ;

Zhang, Jianping ;

Yang, Lihua ;

Li, Lei ;

Li, Yuan .

CELL DEATH DISCOVERY, 2019, 5 (1)

[83] Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro [J].

Qu, Zhen ;

Wu, Junhua ;

Wu, Junyi ;

Luo, Dongjun ;

Jiang, Chunping ;

Ding, Yitao .

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH, 2016, 35 :1-12

[84] High expression of HOXA13 correlates with poorly differentiated hepatocellular carcinomas and modulates sorafenib response in in vitro models [J].

Quagliata, Luca ;

Quintavalle, Cristina ;

Lanzafame, Manuela ;

Matter, Matthias S. ;

Novello, Chiara ;

di Tommaso, Luca ;

Pressiani, Tiziana ;

Rimassa, Lorenza ;

Tornillo, Luigi ;

Roncalli, Massimo ;

Cillo, Clemente ;

Pallante, Pierlorenzo ;

Piscuoglio, Salvatore ;

Ng, Charlotte K. Y. ;

Terracciano, Luigi M. .

LABORATORY INVESTIGATION, 2018, 98 (01) :95-105

[85]

Reyes Ryan, 2017, Gene Expression-The Journal of Liver Research, V17, P129, DOI 10.3727/105221616X693855

[86] Complete response under sorafenib in patients with hepatocellular carcinoma: Relationship with dermatologic adverse events [J].

Rimola, Jordi ;

Diaz-Gonzalez, Alvaro ;

Darnell, Anna ;

Varela, Maria ;

Pons, Fernando ;

Hernandez-Guerra, Manuel ;

Delgado, Manuel ;

Castroagudin, Javier ;

Matilla, Ana ;

Sangro, Bruno ;

Rodriguez de Lope, Carlos ;

Sala, Margarita ;

Gonzalez, Carmen ;

Huertas, Carlos ;

Minguez, Beatriz ;

Ayuso, Carmen ;

Bruix, Jordi ;

Reig, Maria .

HEPATOLOGY, 2018, 67 (02) :612-622

[87] Revisiting the role of ABC transporters in multidrug-resistant cancer [J].

Robey, Robert W. ;

Pluchino, Kristen M. ;

Hall, Matthew D. ;

Fojo, Antonio T. ;

Bates, Susan E. ;

Gottesman, Michael M. .

NATURE REVIEWS CANCER, 2018, 18 (07) :452-464

[88] Role of intratumoural heterogeneity in cancer drug resistance: molecular and clinical perspectives [J].

Saunders, Nicholas A. ;

Simpson, Fiona ;

Thompson, Erik W. ;

Hill, Michelle M. ;

Endo-Munoz, Liliana ;

Leggatt, Graham ;

Minchin, Rodney F. ;

Guminski, Alexander .

EMBO MOLECULAR MEDICINE, 2012, 4 (08) :675-684

[89] Treatment Efficacy Differences of Sorafenib for Advanced Hepatocellular Carcinoma: A Meta-Analysis of Randomized Clinical Trials [J].

Shao, Yu-Yun ;

Shau, Wen-Yi ;

Chan, Soa-Yu ;

Lu, Li-Chun ;

Hsu, Chih-Hung ;

Cheng, Ann-Lii .

ONCOLOGY, 2015, 88 (06) :345-352

[90] ETS-1 induces Sorafenib-resistance in hepatocellular carcinoma cells via regulating transcription factor activity of PXR [J].

Shao, Zhiyi ;

Li, Yibo ;

Dai, Wenjie ;

Jia, Hui ;

Zhang, Yingshi ;

Jiang, Qiyu ;

Chai, Yantao ;

Li, Xiaojuan ;

Sun, Huiwei ;

Yang, Ruichuang ;

Cao, Yu ;

Feng, Fan ;

Guo, Yingjie .

PHARMACOLOGICAL RESEARCH, 2018, 135 :188-200

← 4 5 6 7 8 9 10 11 12 13 →